Biased Ligands. Better Drugs.

Investor Inquiries:Erin Clark
Snr Director Corporate Strategy & IR
610-354-8840 x355
ir@trevena.com

PR/Media Inquiries:pr@trevena.com

Press Releases

Recent News

November 8, 2018 Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring

November 2, 2018 Trevena Receives Complete Response Letter for Oliceridine from FDA

October 12, 2018 Trevena to Present Phase 3, Open-Label Safety Study of Oliceridine at the American Society of Anesthesiologists Annual Meeting

October 11, 2018 Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome

October 11, 2018 Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain

October 1, 2018 Trevena announces completion of leadership transition and appointment of new director

September 10, 2018 Trevena to Present Oliceridine, a Next Generation IV Opioid for the Management of Moderate to Severe Acute Pain, at FDA Advisory Committee Meeting on October 11, 2018

August 30, 2018 Trevena to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

August 2, 2018 Trevena Reports Second Quarter 2018 Financial Results

June 28, 2018 Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine

June 11, 2018 Trevena Expands Commercial and Medical Affairs Leadership Teams with Key Hires

May 30, 2018 Trevena to Present at the Jefferies Global Healthcare Conference

May 22, 2018 Trevena announces presentations at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

May 21, 2018 Trevena Appoints Mark A. Demitrack, M.D., as Chief Medical Officer

May 8, 2018 Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 3, 2018 Trevena Reports First Quarter 2018 Financial Results

May 2, 2018 Trevena to Present at the Deutsche Bank 43rd Annual Healthcare Conference

May 1, 2018 Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd Announce License Agreement for Oliceridine in China

April 27, 2018 Trevena and Pharmbio Korea Announce License and Commercialization Agreement for Oliceridine in South Korea

April 26, 2018 Trevena to Report First Quarter 2018 Financial Results on May 3, 2018

April 5, 2018 Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer

March 20, 2018 Trevena to Present at the Needham & Company 17th Annual Healthcare Conference

March 14, 2018 Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference

March 7, 2018 Trevena to Present at the Cowen and Company 38th Annual Healthcare Conference

March 7, 2018 Trevena Reports Full Year 2017 Earnings

March 2, 2018 Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 28, 2018 Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results

February 2, 2018 Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating Officer

January 2, 2018 Trevena Announces FDA Acceptance for Review of New Drug Application for Oliceridine Injection

Copyright © Trevena, Inc.